



Press Release

March 7, 2018

Strides Shasun Limited
(Formerly Strides Arcolab Limited)
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun to launch Ranitidine 75mg OTC Tablets

Approval from 50:50 JV with Vivimed Labs Product strengthens Strides Ranitidine portfolio in the US markets

Bangalore, March 7, 2018 Strides Shasun Limited today announced that it will launch **Ranitidine Tablets USP, 75 mg (OTC)** for the US markets. The new launch further strengthens Strides' Ranitidine portfolio that now includes **Ranitidine Tablets 150 mg and 300 mg** in the Rx space and **Ranitidine Tablets 75 mg and 150 mg** in the OTC space. Strides is already a key player with 32% share of the US Rx market for Ranitidine. According to IRI data, the US OTC market for **Ranitidine Tablets**, which is the generic form of the popular brand **Zantac**, is approximately USD 200 Million.

This is the second product approval from company's 50:50 JV with Vivimed Labs. The product will be backward integrated and will be manufactured at the JV's Oral dosage facility in Chennai. Strides will have exclusive marketing rights for the product in the US. The product will be launched immediately.

The company has 82 cumulative ANDA filings with USFDA (including its JV with Vivimed) of which 51 ANDAs have been approved as of date and 31 are pending approval.

About Ranitidine Tablets

Ranitidine belongs to a class of drugs known as H2 histamine blockers. It is used to treat peptic ulcers of the stomach and intestines and gastroesophageal reflux and heartburn related to indigestion.

About Strides Shasun

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has three business verticals, viz., Regulated Markets, Emerging Markets and Active Pharmaceutical Ingredients.

The Company has global manufacturing foot print with 9 manufacturing facilities spread across three continents including 7 US FDA approved facilities and 2 facilities for the emerging markets. The Company has two dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at www.stridesarco.com

For further information, please contact:

<p><u>Strides:</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: investors@stridesshasun.com</p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com</p> <p>K Priya: +91 9535425418 priya@fortunapr.com</p>
--	--